NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in

Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in global phase III NANORAY-312 study; US and Asia site activation expected in 2022

Priority NBTXR3 plus anti-PD-1 combination program poised to advance as the Company seeks to define registration pathway with regulatory agencies based on initial data from ongoing phase I immunotherapy study

Operating runway extended into second quarter 2023 as a result of enhancing operational efficiencies and optimizing capital allocation for continued investment in priority development pathways

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--January 10, 2022--Regulatory News:

NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided a corporate update

highlighting key priorities and anticipated development milestones for 2022.

"We believe 2021 provided strong validation of the broad potential therapeutic benefit of NBTXR3 and the capabilities of the Nanobiotix team," said Laurent Levy, co-founder and chairman of the executive board of Nanobiotix. "Not only did our

single-agent and combination development programs yield new data suggesting radiotherapy-activated NBTXR3 may improve clinical outcomes for patients with either local or systemic disease, but we were also able to launch NANORAY-312, our global

phase III registration study in head and neck cancer. This momentum enabled us to move quickly to begin 2022, with the first European patient randomized in our phase III study and recruitment efforts well under way. In parallel, in 2021 we

strengthened our leadership team with the appointment of both a new supervisory board Chairman and new Chief Financial Officer; and added a new strategic partner to advance and expand development of NBTXR3 in Asia. Moreover, we took measures to

increase operational efficiencies and optimize capital allocation, effectively extending our operating runway while further strengthening our priority development pathways. Our priorities for the year remain focused on executing our ongoing

studies, capturing the opportunity to drive value by defining our registration strategy in immunotherapy, and expanding the tumor-agnostic, combination-agnostic profile of NBTXR3 through our strategic collaborations."

2022 Corporate Priorities

The Nanobiotix mission is to improve treatment outcomes for patients around the world by developing and commercializing disruptive, nanophysics-based therapeutic solutions across multiple major disease areas, beginning with cancer. In 2022,

Nanobiotix plans to continue to grow and strengthen its organizational capabilities in order to deliver on the potential of its lead product candidate, NBTXR3.

Key corporate priorities for the year are as follows:

Focus Company-led development efforts on the execution of NANORAY-312, a global, pivotal study seeking regulatory market approval of NBTXR3 as a single-agent activated by radiation in locally advanced head and neck squamous cell carcinoma

(HNSCC; head and neck cancer) and the advancement of a follow-on checkpoint inhibitor combination strategy for patients na ve to anti-PD-1 treatment as well as patients with inadequate or no response to prior anti-PD-1 treatment

Advance the expansion of NBTXR3's global pipeline through existing collaborations and/or the addition of new collaborations that can potentially contribute complementary development and/or commercial capabilities

Further align resources and capital allocation with strategic priorities and enhance operating efficiencies

Deepen operational expertise in key functional areas to support continued company growth

Continue to foster a company culture of innovation, integrity, accountability, transparency, and inclusion

2022 Development Pipeline Objectives

In 2022, the Nanobiotix development program will continue to focus on: (i) Execution of Company-led priority pathways in HNSCC and immunotherapy, and (ii) working with existing and future collaborators to expand the development footprint for

Key development objectives and expected milestones as follows:

Advance toward NBTXR3 global commercial registration through NANORAY-312, evaluating the product candidate as a single-agent activated by radiotherapy for high-risk elderly patients with locally advanced HNSCC following preliminary

survival data from phase I dose expansion study (Study 102 Expansion) showing a potential benefit for elderly patients with a worse prognosis. Expected 2022 milestones include:

Randomize First NANORAY-312 Patient in Europe - January 2022 (Achieved)

Activate First NANORAY-312 US Site

Activate First NANORAY-312 Asia Site (LianBio)

Establish a planned path to registration for NBTXR3 in combination with anti-PD-1 following initial data from the Company's ongoing phase I study (Study 1100) suggesting NBTXR3 may prime immune response, enhance response rates in anti-PD-1

na ve patients, and help overcome resistance to prior anti-PD-1 therapy in non-responders. Expected 2022 milestones include:

Establish Recommended Phase II Dose (RP2D) in all cohorts

Present Updated Study 1100 Data

Announce Development Next Steps Following Regulatory Agency Feedback

Expand evaluation of NBTXR3 safety and feasibility to additional solid tumor indications and therapeutic combinations outside of Company-led pathways through collaborators. Expected 2022 milestones include:

Establish Recommended Phase II Dose (RP2D) in Pancreatic Cancer

Present Data from Phase I evaluation of NBTXR3 plus chemoradiation in HNSCC

Present Data from Phase I/II evaluation of NBTXR3 plus chemoradiation in Rectal Cancer

As of December 31, 2021, Nanobiotix estimates that it had approximately 83.9 million in cash, cash equivalents, and investments, compared to 119.2 million as of December 31, 2020. Following comprehensive operational adjustments undertaken

in the second half of 2021, Nanobiotix has been able to extend its operating runway and now expects that its cash, cash equivalents, and investments as of December 31, 2021, excluding any future potential milestones that may be received by the

Company from collaborations, will enable the Company to fund its current operational plan into the second quarter of 2023. This estimate of cash, cash equivalents and investments is preliminary and is based on information currently available

and may differ from the actual cash balance to be included in the Company's audited financial statements.

Upcoming Investor Conferences in January 2022

H.C. Wainwright Bioconnect Conference

Date: January 10-13, 2022

Format: Corporate presentation

Time: Presentation available for registered attendees starting January 10, 2022 at 7:00 AM (EST) / 1:00 PM (CET)

Biotech Showcase 2022

Date: January 17-19, 2022

Format: Corporate presentation and virtual one-on-one meetings with investors

Time: Presentation available for registered attendees starting January 10, 2022 at 7:00 AM (EST) / 1:00 PM (CET)

An updated corporate overview presentation is available on the Investors section of the Company's website at https://www.nanobiotix.com/stock-information and a webcast of the H.C. Wainwright Bioconnect Conference will be archived in the

events section at https://www.nanobiotix.com/events.

2022 Financial Agenda

March 30, 2022 - 2021 Full-Year Corporate and Financial Update

May 10, 2022 - First Quarter 2022 Corporate and Financial Update

June 17, 2022 - Annual General Meeting, Paris, France

September 7, 2022 - 2022 Half-Year Corporate and Financial Update

November 9, 2022 - Third Quarter 2022 Corporate and Financial Update

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The product candidate's physical

mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA,

Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway. The company-sponsored phase I dose escalation and dose expansion study has produced favorable safety data and

early signs of efficacy. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of

patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

Nanobiotix has also prioritized an Immuno-Oncology development program-beginning with a Company sponsored phase I clinical study evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors for patients with

locoregional recurrent or recurrent/metastatic HNSCC and lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy either na ve or resistant to prior PD-1 (either primary or secondary as per SITC criteria).

Given the Company's focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in strategic collaborations to expand development of the product candidate in parallel with its priority development pathways.

Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several phase I and phase II studies to evaluate NBTXR3 across

tumor types and therapeutic combinations. In 2021, the Company entered into an additional strategic collaboration agreement with LianBio to support its global phase III study in Asia along with four future registrational studies.

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for

humanity. The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, Germany and Switzerland.

Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The

company's resources are primarily devoted to the development of its lead product candidate- NBTXR3 -which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients

with soft tissue sarcoma under the brand name Hensify .

This press release contains certain "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such

as "at this time," "anticipate," "believe," "expect," "intend," "on track," "plan," "scheduled," and "will," or the negative of these and similar expressions. These forward-looking statements, which are based on our management's current

expectations and assumptions and on information currently available to management, include statements about the timing and progress of clinical trials, the timing of our presentation of data, the results of our preclinical and clinical

studies and their potential implications. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However, these forward-looking

statements are subject to numerous risks and uncertainties, including with respect to the risk that subsequent studies and ongoing or future clinical trials may not generate favorable data notwithstanding positive early clinical results and

the risks associated with the evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to it. Furthermore, many other important factors, including those described

in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 7, 2021 under "Item 3.D. Risk Factors" and those set forth in the universal registration document of Nanobiotix filed with the French

Financial Markets Authority (Autorit des March s Financiers - the AMF) on April 7, 2021, each as updated in our Half-Year Financial Report filed with the AMF and the SEC on September 8, 2021 (a copy of which is available on

www.nanobiotix.com), as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or

implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in

the forward-looking statements, even if new information becomes available in the future.

2022 Development Outlook Overview

Communications Department

Investor Relations Department

SVP, Investor Relations

FR - Ulysse Communication

Pierre-Louis Germain